Company Filing History:
Years Active: 2024
Title: Innovations by Robin Mansukhani in Immunotherapy
Introduction
Robin Mansukhani is an accomplished inventor based in San Francisco, CA. He has made significant contributions to the field of immunotherapy, particularly in the activation of invariant natural killer T-cells. His work focuses on developing compounds that can enhance the immune response against inflammatory senescent cells.
Latest Patents
Mansukhani holds a patent for "Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells." This patent describes compounds that activate invariant natural killer T (iNKT) cells, leading to an increase in the production of various cytokines, including IFNγ, IL-2, IL-4, IL-6, and TNFα. The activated iNKT cells can selectively reduce or eliminate inflammatory senescent cells, which are known to contribute to various age-related diseases.
Career Highlights
Robin Mansukhani is associated with Deciduous Therapeutics, Inc., where he continues to advance his research in immunotherapy. His innovative approach to targeting senescent cells has the potential to revolutionize treatments for chronic inflammatory conditions.
Collaborations
Mansukhani collaborates with Thomas Bobinski, leveraging their combined expertise to further their research and development efforts in the field of immunotherapy.
Conclusion
Robin Mansukhani's work exemplifies the intersection of innovation and healthcare, showcasing how targeted therapies can address complex medical challenges. His contributions to the field of immunotherapy are paving the way for new treatment options.